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ABSTRACT 
Objective: To evaluate real-world outcomes in patients with type 2 diabetes mellitus (T2DM) 
receiving basal insulin, who initiate add-on therapy with a rapid-acting insulin (RAI) or a 
glucagon-like peptide 1 (GLP-1) receptor agonist. 
Methods: Data were extracted retrospectively from a U.S. health claims database. Adults with 
T2DM on basal insulin who added an RAI (basal+RAI) or GLP-1 receptor agonist (basal+GLP-
1) were included. Propensity score matching (1 up to 3 ratio) was used to control for differences 
in baseline demographics, clinical characteristics, and health resource utilization. Endpoints 
included prevalence of hypoglycemia, pancreatic events, all-cause and diabetes-related 
resource utilization, and costs at 1 year follow-up. 
Results: Overall, 6,718 matched patients were included: 5,013 basal+RAI and 1,705 
basal+GLP1. Patients in both groups experienced a similar proportion of any hypoglycemic 
event (P = .4079). Hypoglycemic events leading to hospitalization were higher in the basal+RAI 
cohort (2.7% vs. 1.8%; P = .0444). The basal+GLP-1 cohort experienced fewer all-cause 
(13.55% vs. 18.61%; P<.0001) and diabetes-related hospitalizations (11.79% vs. 15.68%; 
P<.0001). The basal+GLP-1 cohort had lower total all-cause health care costs ($18,413 vs. 
$20,821; P = .0002), but similar diabetes-related costs ($9,134 vs. $8,985; P<.0001) compared 
with the basal+RAI cohort. 
Conclusion: Add-on therapy with a GLP-1 receptor agonist in T2DM patients receiving basal 
insulin was associated with fewer hospitalizations and lower total all-cause costs compared with 
add-on therapy using a RAI, and could be considered an alternative to a RAI in certain patients 
with T2DM, who do not achieve effective glycemic control with basal insulin. 
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Abbreviations 
A1C = hemoglobin A1C; ED = emergency department; GLP-1 = glucagon-like peptide 1; 
ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification; 
IHCIS = Integrated Health Care Information Services; NPH = neutral protamine Hagedorn; 
PSM = propensity score matching; RAI = rapid-acting insulin; T2DM = type 2 diabetes mellitus. 
 
 
INTRODUCTION 
Many patients with type 2 diabetes mellitus (T2DM) will require insulin therapy as an additional 
treatment on top of metformin to achieve or maintain target glycemic control (1). However, a 
substantial proportion (estimates ranging from 28–72%) of patients might not achieve glycemic 
control on basal insulin therapy alone and could require further treatment intensification (2-5). 
One method of intensifying basal insulin therapy is to add a prandial or rapid-acting insulin 
(RAI), but treatment intensification with a glucagon-like peptide 1 (GLP-1) receptor agonist 
might be an effective alternative (1,6). Several clinical trials have reported an association 
between the addition of a GLP-1 receptor agonist (e.g., exenatide, lixisenatide) to basal insulin 
therapy (e.g., insulin glargine, insulin detemir, neutral protamine Hagedorn [NPH] insulin) and 
improved glycemic control, without an accompanying increase in weight or risk of hypoglycemia 
(7-12). Thus, this combination might represent an additional option for patient management. 
Real-world data on the effects of newly-emerging therapeutic options, such as the 
intensification of basal insulin therapy with a GLP-1 receptor agonist, compared with pre-
established regimens are crucial if health care providers, payers, and other decision makers are 
to continue selecting the most appropriate and cost-effective treatments for patients. The clinical 
studies reported previously have not included economic outcomes, a necessary component of 
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current clinical decision-making. This study used the Integrated Health Care Information 
Services (IHCIS) IMPACT database to evaluate real-world outcomes, both clinical and 
economic, associated with the use of basal insulin plus a GLP-1 receptor agonist, compared 
with basal insulin plus an RAI, in patients with T2DM in the United States in a managed-care 
setting. 
 
METHODS 
Study Design 
This was a retrospective analysis of U.S. health insurance claims data from the IHCIS IMPACT 
database, which contains medical and pharmacy claims, eligibility data, and laboratory results 
from 86.4 million covered lives. Of these, 63.7 million (74%) have pharmacy benefits and 12.6 
million (15%) have laboratory results; the database includes all data for individuals in all U.S. 
census regions and represents 46 health plans. Institutional Review Board approval to conduct 
this study was not required. 
 
Patient Identification 
Data were included from patients aged ≥18 years and diagnosed with T2DM; defined as having 
≥1 inpatient or ≥2 office visits (≥30 days apart) with a primary or secondary T2DM diagnosis 
(International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] 
diagnosis codes 250.x0 or 250.x2) (13). Patients were treated with a basal insulin (insulin 
glargine, insulin detemir, or NPH insulin) plus add-on therapy with either an RAI (insulin 
glulisine, insulin aspart, or insulin lispro; the basal+RAI group) or a GLP-1 receptor agonist 
(exenatide or liraglutide; the basal+GLP-1 group), initiated between July 1, 2007, and December 
31, 2011. In addition, continuous health care coverage for ≥6 months before (baseline) and for 
12 months after (follow-up) the first GLP-1 receptor agonist or RAI prescription date (index date) 
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was required for inclusion, and patients had to have been prescribed basal insulin in the quarter 
before and the quarter after the index date. Subsets of patients with ≥1 glycated hemoglobin 
A1C (A1C) value during the baseline period or aged ≥55 years at index were also identified for 
sensitivity analyses. Data from patients prescribed: premix, prandial, or regular insulin; a GLP-1 
receptor agonist; or ≥1 type of basal insulin during the baseline period were excluded from the 
analysis. 
 
Study Endpoints 
Clinical outcomes included: hypoglycemic events, defined as a health care encounter 
(outpatient, inpatient, or emergency department [ED] visit) with a primary or secondary 
diagnosis code for hypoglycemia (ICD-9-CM diagnosis codes: 250.8x, diabetes with other 
specified manifestations; 251.0, hypoglycemic coma; 251.1, other specified hypoglycemia; or 
251.2, hypoglycemia, unspecified); and pancreatic events, defined as a health care encounter 
(outpatient, inpatient, or ED visit) with a primary or secondary diagnosis of pancreatic disease 
(ICD-9-CM diagnosis code 577.xx). 
Economic outcomes included all-cause health care resource utilization (outpatient visits, 
ED visits, inpatient admissions, inpatient length of stay), diabetes-related health care resource 
utilization (from claims with a primary or secondary diagnosis of diabetes [ICD-9-CM diagnosis 
code 250.xx]), and health care costs. These were computed as plan-reimbursed amounts of 
adjudicated claims including inpatient, outpatient, ED, and pharmacy costs. Diabetes-related 
health care costs comprised those from medical claims with a primary or secondary diagnosis of 
diabetes (ICD-9-CM diagnosis code 250.xx), antidiabetes medications, glucose meters, and test 
strips. 
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Statistical Analyses 
Patient baseline demographics, including age, gender, health plan type, and U.S. geographic 
region, were assessed at the study index date, whereas baseline clinical characteristics 
(Charlson Comorbidity Index and individual comorbidities) were observed during the 6 months 
prior to the index date. Study outcomes were measured at 1-year follow-up. 
Propensity score matching (PSM; 1 up to 3 ratio) was used to control for any differences 
in age, gender, health plan, comorbidity, all-cause health care utilization (including any 
hospitalization and any ED visit), and hypoglycemic events between cohorts at baseline. 
Baseline characteristics and clinical and economic outcomes were summarized and compared 
in matched cohorts, with P-values provided by Student t-tests for continuous variables, or χ2 
tests for binary and categorical variables, as appropriate; health care costs were reported as 
mean costs and cost difference in U.S. dollars. 
 
RESULTS 
Baseline Demographics and Clinical Characteristics 
Patient sample attrition associated with the inclusion criteria for this study is shown in Figure 1. 
In total, data from 11,338 patients were eligible for inclusion, 1,705 in the basal+GLP-1 group 
and 9,633 in the basal+RAI group. At baseline, patients in the unmatched basal+RAI group had 
more comorbidities, higher A1C values, and higher healthcare costs than those in the 
basal+GLP-1 group (Table 1). After PSM, data from 6,718 patients were retained for the 
analysis. In the basal+GLP-1 group (n = 1,705), 82% of patients used exenatide and 18% used 
liraglutide. In the basal+RAI group (n = 5,013), 49% of patients used insulin aspart, 44% insulin 
lispro, and 7% insulin glulisine. At baseline, in the PSM-patients overall, 47% of the patients 
were women, mean age was 54 years, and basal insulin use was 79% insulin glargine, 16% 
insulin detemir, and 5% NPH. 
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Selected Clinical Outcomes 
Clinical outcomes after 1 year of follow-up are shown in Table 2. The proportions of patients in 
the basal+GLP-1 and basal+RAI groups who experienced either any hypoglycemic event or any 
pancreatic event were similar. However, inpatient hypoglycemic events were significantly less 
common in the basal+GLP-1 group compared with the basal+RAI group (0.12% vs. 0.46%; 
P = .0454) as were hypoglycemic events leading to hospitalization (1.82% vs. 2.69%; 
P = .0444). 
 
Health Care Resource Utilization 
In general, fewer health care resources were required by the basal+GLP-1 group. All-cause 
hospitalizations were significantly less common in the basal+GLP-1 group compared with the 
basal+RAI group (Fig. 2A), and there were significantly fewer diabetes-related hospitalizations 
and ED visits in the basal+GLP-1 group compared with the basal+RAI group (Fig. 2B). 
However, all-cause and diabetes-related endocrinologist visits were significantly higher in the 
basal+GLP-1 group compared with the basal+RAI group (Fig. 2). 
With regard to cost outcomes, mean total all-cause health care costs were significantly 
lower in the basal+GLP-1 group compared with the basal+RAI group, driven by significantly 
lower inpatient (cost difference = $2,051; P<.0001) and outpatient costs (cost difference = 
$1,682; P<.0001) (Fig. 3A). Pharmacy costs were significantly higher in the basal+GLP-1 group 
versus basal+RAI group (Fig. 3A). For diabetes-related health care costs, the basal+GLP-1 
group compared with the basal+RAI group had significantly lower inpatient (cost difference = 
$530; P = .0192) and outpatient costs (cost difference = $353; P<.0001), and lower costs 
related to diabetes supplies and testing strips (Fig. 3B). This was offset by significantly lower 
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diabetes-related pharmacy costs in the basal+RAI group; total costs for diabetes-related health 
care were not significantly different between groups (Fig. 3B). 
 
Sensitivity Analyses 
Similar trends in clinical and economic outcomes were observed in sensitivity analyses 
conducted in A1C-matched patient cohorts, which comprised approximately 20% of the overall 
population (Table 3). In this matched cohort, changes in A1C values at 1-year were similar in 
the basal+RAI and basal+GLP-1 groups (−0.58% vs. −0.60%, respectively; P = .9104).  
 
DISCUSSION 
This study presented real-world data on clinical, health care resource utilization, and cost 
outcomes in T2DM patients not achieving glycemic control, who initiated basal insulin therapy 
combined with a GLP-1 receptor agonist or an RAI in a U.S. managed-care setting.  
There were no differences in A1C outcomes in patients adding a GLP-1 receptor agonist 
or RAI, or  in terms of hypoglycemic and pancreatic events, although there were fewer 
hypoglycemic events leading to hospitalization in the basal+GLP-1 group compared with the 
basal+RAI group. Intensification of treatment with a GLP-1 receptor agonist was associated with 
fewer diabetes-related hospitalizations and ED visits than intensification with RAI; however, 
GLP-1 receptor agonist use was associated with more diabetes-related endocrinologist visits. 
This could indicate a potential association between GLP-1 receptor agonist usage and 
increased endocrinologist visits. Other work has suggested that, even as recently as in 2013, 
endocrinologists feel more confident than other health care providers in identifying patients who 
would benefit from treatment with a GLP-1 receptor agonist (14).    
Inpatient and outpatient health care costs were significantly lower in the basal+GLP-1 
group compared with the basal+RAI group, regardless of whether all-cause or diabetes-related 
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health care costs were being evaluated. In contrast, all-cause and diabetes-related pharmacy 
costs were significantly higher in the basal+GLP-1 group compared with the basal+RAI group. 
However, the basal insulin plus GLP-1 receptor agonist regimen cost an average of $2,408 less 
annually in terms of total all-cause health care costs compared with the basal insulin plus RAI 
regimen.  
In our study, of the >11,000 patients identified, 85% intensified with an RAI. Although 
GLP-1 receptor agonist treatment would not be seen as appropriate for all patients, our study 
has demonstrated that in patients with similar baseline demographic and clinical characteristics 
there might be reduction in overall costs if a GLP-1 receptor agonist were used. Furthermore, 
when patients initiating a GLP-1 receptor agonist or RAI were matched according to their 
baseline A1C values, we continued to observe the difference in overall costs with similar 
glycemic outcomes.  
. Evidence from clinical studies and a recent systematic review also support the consideration of 
GLP-1 receptor agonist as add-on therapy for treatment intensification in patients on basal 
insulin therapy (6-9,11,12). However, none of these previous studies included cost outcomes. 
These favorable clinical trial data were also reflected in another real-world data analysis of 
6,500-matched cohort patients. In this other real-world data analysis, treatment intensification 
using a GLP-1 receptor agonist was associated with similar glycemic control, higher weight loss, 
and lower incidence of hypoglycemia compared with intensification using an RAI (10), 
complementing the current study. 
 
Limitations 
As with all retrospective database analyses, this study could be subject to selection bias; 
however, PSM was undertaken to mitigate the effects of confounding factors. Although one-to-
many matching has been previously validated as a method to increase precision in cohort 
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studies as compared with one-to-one matching (15), we were unable to control for certain 
characteristics at baseline (e.g., A1C values, body weight, and duration of disease) so no 
causality conclusions can be drawn from this study. These factors are associated with the 
severity of the disease and may have an important impact on clinical outcomes as well as 
healthcare utilization and costs. 
 In addition, the health care claims data used in this study could be subject to coding 
errors because the presence of an ICD-9-CM diagnosis code on a medical claim does not 
confirm a positive presence of disease, also a diagnosis might be incorrectly coded or included 
as a rule-out criterion rather than actual disease. Similarly, hypoglycemia was estimated using 
diagnostic codes in which only events severe enough to require medical intervention are 
captured. Furthermore, the current results are from a typical managed-care U.S. population. For 
example, the proportion of patients in this managed care database aged 65 years and older was 
low at 6.7% of all members, and fewer than 5% of patients with diabetes had Medicare or 
Medicaid coverage. Caution should be exercised in the generalization of these results to other 
populations.   
 
CONCLUSION 
Certain patients on basal insulin who are not achieving/maintaining glycemic control targets and 
who require intensification of their treatment, as their disease progresses, could be considered 
for add-on treatment with a GLP-1 receptor agonist rather than with an RAI. Longer-term studies 
are required to further evaluate the potential clinical and economic benefits associated with the 
use of a GLP-1 receptor agonist in patients not achieving adequate glycemic control on basal 
insulin plus oral antidiabetes drugs alone. 
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FIGURE LEGENDS 
 
Fig. 1. Sample attrition. GLP-1 = glucagon-like peptide 1 receptor agonist; ICD-9-CM = 
International Classification of Diseases, Ninth Revision, Clinical Modification; RAI = rapid-acting 
insulin; T2DM = type 2 diabetes mellitus. 
 
Fig. 2. Health care resource utilization at 1-year follow-up (matched analysis): all-cause (A) and 
diabetes-related (B). ED = emergency department; GLP-1 = glucagon-like peptide 1 receptor 
agonist; RAI = rapid-acting insulin. 
 
Fig. 3. Health care costs at 1-year follow-up (matched analysis): all-cause (A) and diabetes-
related (B). ED = emergency department; GLP-1 = glucagon-like peptide 1 receptor agonist; 
RAI = rapid-acting insulin. 
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Table 1 
Baseline Demographic and Clinical Characteristics (Unmatched Analysis) 
Characteristic Basal+RAI 
(n = 9,633) 
Basal+GLP-1 
(n = 1,705) 
P-value 
Age, mean (SD), years 54.37 (12.16) 54.36 (9.17) .9718 
Women, n (%) 4,319 (44.84) 805 (47.21) .0689 
U.S. region, n (%)    
Northeast 2,711 (28.14) 466 (27.33) .4916 
South 4,087 (42.43) 731 (42.87) .7308 
Midwest 1,925 (19.98) 337 (19.77) .8355 
West 908 (9.43) 171 (10.03) .4339 
Unknown 2 (0.02) 0 .5518 
Health plan type, n (%)    
HMO 1,696 (17.61) 307 (18.01) .6900 
POS 4,841 (50.25) 924 (54.19) .0027 
PPO 2,051 (21.29) 351 (20.59) .5115 
Medicare 404 (4.19) 40 (2.35) .0003 
Medicaid 75 (0.78) 11 (0.65) .5584 
Others 566 (5.88) 72 (4.22) .0063 
CCI, mean (SD) 0.92 (1.59) 0.50 (0.98) <.0001 
A1C    
Evaluable at baseline, n (%) 1,819 (18.88) 401 (23.52) <.0001 
<7.0% 193 (10.61) 56 (13.97) .0540 
≥7.0% to <8.0% 349 (19.19) 93 (23.19) .0690 
≥8.0% to <9.0% 377 (20.73) 99 (24.69) .0801 
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Characteristic Basal+RAI 
(n = 9,633) 
Basal+GLP-1 
(n = 1,705) 
P-value 
≥9.0% 900 (49.48) 153 (38.15) <.0001 
Mean (SD), %  9.23 (2.01) 8.71 (1.68) <.0001 
All-cause health care costs, mean (SD), $    
Total costs 13,546 (28,216) 7,527 (10,260) <.0001 
Inpatient costs 6,214 (23,458) 1,427 (7,945) <.0001 
Outpatient costs 4,119 (9,898) 2,680 (4,493) <.0001 
ED costs 401 (1,488) 248 (1,044) <.0001 
Treatment costs 2,813 (2,978) 3,173 (2,486) <.0001 
Diabetes-related health care costs, mean 
(SD), $ 
   
Total costs 4,898 (10,429) 3,410 (5,288) <.0001 
Inpatient costs 2,372 (9,638) 714 (4,728) <.0001 
Outpatient costs 1,103 (2,681) 928 (1,701) .0004 
ED costs 181 (808) 112 (579) <.0001 
Treatment costs 1,048 (892) 1,475 (1,008) <.0001 
Diabetes supply costs 194 (229) 182 (202) .0196 
Cost of testing strips 155 (210) 138 (188) .0008 
CCI = Charlson Comorbidity Index; ED = emergency department; GLP-1 = glucagon-like 
peptide 1 receptor agonist; HMO = Health Maintenance Organization; POS = Point-of-Service; 
PPO = Preferred Provider Organization; RAI = rapid-acting insulin; SD = standard deviation. 
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Table 2 
Selected Clinical Endpoints at 1-Year Follow-Up (Matched Analysis) 
Endpoint Basal+RAI 
(n = 5,013) 
Basal+GLP-1 
(n = 1,705) 
P-value 
Hypoglycemic events, n (%)    
Any 359 (7.16) 112 (6.57) .4079 
Any inpatient 23 (0.46) 2 (0.12) .0454 
Any ED 117 (2.33) 29 (1.70) .1215 
Any outpatient 254 (5.07) 88 (5.16) .8782 
Leading to hospitalizationa 135 (2.69) 31 (1.82) .0444 
Pancreatic events, n (%)    
Any 93 (1.86) 20 (1.17) .0585 
Any inpatient 21 (0.42) 3 (0.18) .1464 
Any ED 35 (0.70) 10 (0.59) .6253 
Any outpatient 69 (1.38) 14 (0.82) .0730 
aDefined as inpatient or ED health care encounters with a primary or secondary ICD-9-CM 
diagnosis code for hypoglycemia. 
ED = emergency department; GLP-1 = glucagon-like peptide 1 receptor agonist; ICD-9-CM = 
International Classification of Diseases, Ninth Revision, Clinical Modification; RAI = rapid-acting 
insulin. 
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Table 3 
Clinical and Economic Endpoints at 1-Year Follow-Up (Matched Analysis of Patients With 
>1 A1C Value During the Baseline Period) 
Endpoint Basal+RAI 
(n = 1,127) 
Basal+GLP-1 
(n = 400) 
P-value 
Hypoglycemic events, n (%)    
Any 87 (7.72) 24 (6.00) .2551 
Any inpatient 6 (0.53) 0 .1437 
Any ED 28 (2.48) 9 (2.25) .7933 
Any outpatient 60 (5.32) 18 (4.50) .5202 
Leading to hospitalizationa 33 (2.93) 9 (2.25) .4762 
Pancreatic events, n (%)    
Any 25 (2.22) 5 (1.25) .2306 
Any inpatient 1 (0.09) 1 (0.25) .4436 
Any ED 14 (1.24) 2 (0.50) .2104 
Any outpatient 19 (1.69) 4 (1.00) .3333 
All-cause health care resource utilization, n 
(%)    
Any hospitalization 245 (21.74) 59 (14.75) .0026 
ED visits 377 (33.45) 127 (31.75) .5341 
Office visits 1,126 (99.91) 400 (100) .5512 
Endocrinologist visits 553 (49.07) 219 (54.75) .0509 
Diabetes-related health care resource 
utilization, n (%)    
Any hospitalization 213 (18.90) 53 (13.25) .0105 
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Endpoint Basal+RAI 
(n = 1,127) 
Basal+GLP-1 
(n = 400) 
P-value 
ED visits 245 (21.74) 81 (20.25) .5324 
Office visits 1,121 (99.47) 398 (99.50) .9386 
Endocrinologist visits 543 (48.18) 217 (54.25) .0370 
All-cause health care costs, mean (SD), $    
Total cost 22,305 (34,986) 19,230 (18,354) .0269 
Inpatient cost 6,412 (24,913) 3,739 (13,184) .0072 
Outpatient cost 7,940 (15,036) 6,089 (7,659) .0017 
ED cost 593 (1,737) 605 (1,790) .9073 
Pharmacy cost 7,361 (5,172) 8,797 (5,078) <.0001 
Diabetes-related health care costs, mean 
(SD), $    
Total cost 9,168 (11,949) 9,522 (9,328) .5464 
Inpatient cost 2,265 (9,765) 1,924 (7,468) .4706 
Outpatient cost 2,283 (4,693) 1,915 (3,388) .0948 
ED cost 274 (1,101) 238 (935) .5340 
Pharmacy cost 3,639 (2,227) 4,929 (2,291) <.0001 
Diabetes supply cost 708 (641) 516 (443) <.0001 
Cost of testing strips 557 (564) 358 (382) <.0001 
aDefined as inpatient or ED health care encounters with a primary or secondary ICD-9-CM 
diagnosis code for hypoglycemia. 
ED = emergency department; GLP-1 = glucagon-like peptide 1 receptor agonist; ICD-9-CM = 
International Classification of Diseases, Ninth Revision, Clinical Modification; RAI = rapid-acting 
insulin; SD = standard deviation 





